X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
P-Esbp-DOX, a novel anti-cancer drug, reported therapeutic success when tested in vivo showed promising results in a mouse model of aggressive liver metastasis of colorectal cancer.
Lead Product(s): P-Esbp Conjugated Doxorubicin
Therapeutic Area: Oncology Product Name: P-Esbp-DOX
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ben-Gurion University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
In a trial evaluating Vaxil's lead product ImMucin™, the mice have received two of the three scheduled vaccinations. USAMRIID reports that the mice appear to be fine having responded normally to the injections administered to date.
Lead Product(s): MUC1-SP-L
Therapeutic Area: Infections and Infectious Diseases Product Name: ImMucin
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
Details:
Vaxil has entered into a cooperative research and development agreement (CRADA) with USAMRIID under which USAMRIID will test CorVax™ for its ability to specifically prevent COVID-19 in mice.
Lead Product(s): CorVax
Therapeutic Area: Infections and Infectious Diseases Product Name: CorVax
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: USAMRIID
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 26, 2020
Details:
The compony has started pre-clinical program for ImMucin™ in combination with P-ESBP, which Vaxil licensed for development and commercialization from BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, Israel.
Lead Product(s): MUC1-SP-L,P-Esbp
Therapeutic Area: Oncology Product Name: ImMucin
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax™, composed of multiple signal peptides.
Lead Product(s): CorVax
Therapeutic Area: Infections and Infectious Diseases Product Name: CorVax
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
This agreement provides Vaxil with vital access to Tel Aviv Medical Center’s research resources including their unique bank of biological samples and its advanced research infrastructure to advance its clinical trials for peptide vaccine development against COVID-19.
Lead Product(s): Peptide based COVID 19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Tel Aviv Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2020
Details:
VXL-301 responded less well in the first preclinical experiment of Vaxil which aimed at testing the immune response of its COVID-19 vaccine candidate.
Lead Product(s): VXL-301
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
Details:
The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Tel Aviv Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
